Abstract 2510
Background
Hand-foot syndrome (HFS) related to new targeted therapies is a common cutaneous toxicity, with potentially serious impacts on the patient QoL. Previous reports indicate that the incidence of HFS was about 30% in apatinib monotherapy for NSCLC. HFS was also reported to be associated with immunotherapy. We conducted a phase II clinical trial on apatinib combined with anti-PD-1 antibody SHR-1210 for advanced NSCLC (No. CTR20170090). Whether the combined therapy leads to a dramatic increase in the incidence of HFS remains uncertain. There are a variety of scales to evaluate the patients’ QoL, but the specific scale for patients with HFS needs further verification.
Methods
Multiply questionnaires including the HFS-specific QoL questionnaire (HFS-14), Dermatology Life Quality Index (DLQI), Skindex-16 and short-form 12 health-related questionnaire (SF-12) were developed to measure the effect of HFS on daily activities. The HFS clinical grade was based on NCI-CTCAE, v3.0.
Results
The validation study included 26 patients, of 21 (80%) developed HFS of varying grades, with 8 (31%) of grade 1, 7 (27%) of grade 2 and 6 (23%) of grade 3. 52% of patients declared involving one limb, and the rest patients developed HFS in both the hands and feet. The mean time to occurring HFS was 30 ± 64 days. In patients with various grades of HFS, the mean HFS-14 and DLQI scores were significantly higher with higher HFS grades, whereas the Skindex-16 and SF-12 scores did not differ. Four kinds of scales analysis also showed significant differences according to the degree of limb involvement, where the scores were significantly higher in patients having both hands and feet severely involved than in those having severe involvement of either only the hands or feet. When in patients with grade 2 HFS, the HFS-14 score was significantly higher in patients involving both the hands and the feet than in patients having only the hands or the feet severely affected; while Skindex-16, DLQI and SF-12 scores have no difference between these two groups.
Conclusions
The incidence of HFS induced by the treatment of anti-PD-1 antibody SHR-1210 combined with apatinib is extremely high. HFS-14 may serve as a more sensitive and valuable tool for early measuring HFS-related QoL impairment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2927 - Singapore Caregiver Quality Of Life Scale (SCQOLS): Turkish Validity and Reliability Study
Presenter: Nur Basak
Session: Poster Display session 3
Resources:
Abstract
5066 - Screening for Psicosocial Distress in recently diagnosed cancer patients
Presenter: Eva Baillès
Session: Poster Display session 3
Resources:
Abstract
6074 - Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a Primary Care Center.
Presenter: Begona Grana Suarez
Session: Poster Display session 3
Resources:
Abstract
5129 - The adhesion in the screening measures in carrying patients of breast cancer and ovary hereditary and the relationship with the psychological aspects
Presenter: Melinda Concepcion
Session: Poster Display session 3
Resources:
Abstract
5635 - Assessment of emotional discomfort of oncological patients in the first nursing visit at Donostia University Hospital
Presenter: Elena Uranga
Session: Poster Display session 3
Resources:
Abstract
858 - A systematic review and meta-analysis of the distress thermometer for the screening of distress in Chinese patients with cancer
Presenter: Hui Hui Sun
Session: Poster Display session 3
Resources:
Abstract
4475 - Pharmacist and Nurse (PN) Led Melanoma Immunotherapy Clinic: Patient Experience Survey
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
1871 - Phone Triage & Acute Review Clinics: The emerging role of the Oncology Specialist Nurse
Presenter: Fiona Barrett
Session: Poster Display session 3
Resources:
Abstract
5193 - Patient reported outcomes during immunotherapy: symptom burden in daily clinical practice
Presenter: José Koldenhof
Session: Poster Display session 3
Resources:
Abstract
2453 - Factors related to hospital length of stay, re-admissions and unplanned care for patients with cancer, an on-going study
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract